Despite a 66% drop from first week sales of 721,000 copies, Coldplay's fourth album Viva la Vida or Death and All His Friends retains the top spot on the Billboard 200, selling 249,000 copies in the album's second week of release. Billboard reported the chart placement Wednesday and noted album sales are down 7.66% in the last week while dropping 13.2% behind the same week totals from one year ago.
The album was released in the United Kingdom three weeks ago tomorrow, while it has only been out in the United States for two weeks. It debuted big in the UK, selling 302,000 copies in the first three days it was out and selling 500,000 copies after ten days. Sales in the U.S. over seven days are obviously larger than the UK figures, pointing to rumored hopes from the band's music label EMI that the album would provide a significant boost for the company during the summer and possibly the year.
I've had the album since it was released, reporting that very day about the packaging of a vinyl and CD copy together that seemed to hint EMI was aware that consumers listen to music more frequently on MP3 players even if they prefer vinyl copies for nostalgia or the entire experience. Two weeks at number is impressive in today's market and even though sales dropped 66%, 249,000 copies is a nice figure for one week. If continued rumors are true that the band will release another album within a year and a half, the future of EMI may be more and more based on the success of one band.
Last updated: February 09, 2012: 05:35 PM
Hot Stocks
DailyFinance Headlines
- Why Groupon Will Never Be Great Again
- Why Used Car Bargains Are Getting Harder to Find
- 5 Reasons Facebook Stock May Be a Better Buy Than You Think
- Department Stores Reveal Top Selling Valentine's Gifts
- Readers' Tips for Financial Renewal, Part 4: Get the Right Job
Benzinga Headlines
- How to Profit off Addicts
- The Pepsi Challenge for 8,700 People is to Find a New Job
- How to Profit From Surging Chinese Prices
- Credit Suisse is the Latest Swiss Bank to Disappoint
- Vodafone Misses Quarterly Revenue
TheFlyOnTheWall.com Headlines
- On The Fly: Closing Wrap
- National Bankshares reports Q4 EPS 70c vs. consensus 64c
- comScore releases January U.S. search engine rankings
- International Game appoints John Vandemore as CFO
- Home Properties sees Q1 FFO 90c-94c vs. consensus 90c
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
WalletPop Headlines
- Why Groupon Will Never Be Great Again
- Why Used Car Bargains Are Getting Harder to Find
- 5 Reasons Facebook Stock May Be a Better Buy Than You Think
- Department Stores Reveal Top Selling Valentine's Gifts
- Readers' Tips for Financial Renewal, Part 4: Get the Right Job
My Portfolios
Track your stocks here!
Find out why more people track their portfolios on AOL Money & Finance then anywhere else.
BloggingStocks Partners
More from AOL Money & Finance
- Business News
- Stock Screener
- Stock Quotes
- Stock Charts
- Banking
- Identity Theft
- DJIA
- Debt Management
- Loans
- Auto Loan
- Mortgages
- Taxes
- Retirement
- Insurance
- Small Business
- Earnings
- Tech News
- Tax Forms
- Tax Deductions
- Tax Credit
- Tax Audit
- Tax Advice
- Stock Ticker
- Stock Brokers
- Resume Builder
- Pig Flu
- Online Tax Filing
- Madoff
- Investing For Retirement
- Income Tax
- Historical Stock Prices
- GOOG
- ETF Investing
- Deals
- DailyFinance
- Crude Oil Prices
- Credit Score Calculator
- Common Tax Filing Mistakes
- AMT
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
The Money Man Behind Rick Santorum: Who Is Foster S. Friess?
Savings Experiment: Snow Removal

